Exagen posts record Q2 revenue $15.1M, raises FY2024 guidance

EXAGEN INC.

2024-Q2 EPS reported -$0.35 revenue$29,479,000

Record total revenue of $15.1M in Q2 2024, up from $14.1M in Q2 2023.
Net loss improved 40.8% to $3.0M; adjusted EBITDA loss improved 53.5% to $1.6M.
Gross margin expanded to 60.1% from 58.7% YoY.
AVISE CTD trailing 12-month ASP reached $401, up 25.3% YoY.
Company raised full-year 2024 revenue and adjusted EBITDA guidance (specific figures not disclosed in release).

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.